The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Optimizing diagnosis and treatment of extranodal NK/T-cell lymphoma
Shinichi Makita, MD, National Cancer Center Hospital, Tokyo, Japan, shares key considerations for clinicians caring for patients with extranodal NK/T-cell lymphoma. He discusses the challenges of diagnosis, the limitations of CHOP-like regimens, and the role of L-asparaginase-based therapies and immune checkpoint inhibitors in the management of relapsed disease. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
